TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02984852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir (DRV)
Description: Darunavir 800 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/TAF(10mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir (DRV)
Description: Darunavir 800 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/TAF(10mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir (DRV)
Description: Darunavir 800 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/TAF(10mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir (DRV)
Description: Darunavir 800 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/TAF(10mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir (DRV)
Description: Darunavir 800 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/TAF(10mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat (COBI)
Description: Cobicistat 150 milligram (mg) will be taken orally in FDC together with DRV(800mg)/FTC(200mg)/TAF(10mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat (COBI)
Description: Cobicistat 150 milligram (mg) will be taken orally in FDC together with DRV(800mg)/FTC(200mg)/TAF(10mg).
Study: NCT00876447

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A 200U
Description: Botulinum toxin Type A 200U injections into the detrusor \> 12 weeks as needed for up to 3 years.
Study: NCT01893658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: administration of a single dose together with the standard treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: standard treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: standard treatment
Study: NCT04507477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: For EBV seropositive lungs meant for an EBV seronegative recipient, one dose of rituximab (500mg) will be added to the EVLP perfusate and be allowed to circulate for 3-4 hours.
Study: NCT02961712

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: single intravenous injection of NK cells (0.9\~1\*10\^9)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: amniotic epithelial cells
Description: single intrathecal injection of amniotic epithelial cells
Study: NCT03508141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate
Description: Experimental

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprecipitate
Description: Comparator
Study: NCT03974113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fitusiran
Description: Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous
Study: NCT03104335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 750 mg daily once oral administration of apatinib for body surface area (BSA) \> 1.5 and 500mg daily for BSA \<1.5. Half an hour after meal and everyday at the same time is usually advised.
Study: NCT02750657

Intervention type: GENETIC
Intervention: Molecular Profiling
Description: Whole Genome Sequencing
Study: NCT03904485

Intervention type: RADIATION
Intervention: cardiac magnetic resonance(CMR) T2 mapping
Description: T2 value before transplant，3 month and 6month after transplant

Intervention type: RADIATION
Intervention: cardiac magnetic resonance(CMR) T2 mapping
Description: T2 value before transplant，3 month and 6month after transplant
Study: NCT03100526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACT Intensive Management
Description: Purpose: Implement a Patient Aligned Care Team (PACT) model that identifies and proactively manages Veterans at the highest risk for hospital admission and death while they are still in the ambulatory care setting.~Goal:~* Reduce emergency department and urgent care utilization, hospitalization, and mortality in complex, high risk patients~* Improve Veteran and staff satisfaction~Objectives:~* Maintain the patient in the home setting as much as possible~* Secure appropriate home environment to facilitate health and well-being~* Utilize comprehensive team-based care~* Engage appropriate VHA programs to provide interdisciplinary, coordinated, and timely management of complex medical issues
Study: NCT02518529

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT
Study: NCT04585178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biobeat patch
Description: The Biobeat device (BB-613WP) is a class IIa medical device and is a non-invasive patch used for monitoring vital signs in clinical and non-clinical settings. The sensor continuously records the photoplethysmographic waveform that allows the calculation of several physiological parameters: heart rate (HR), SPO2, systolic blood pressure (SBP) and change in SBP, diastolic blood pressure (DBP) and change in DBP, stroke volume (SV), cardiac output (CO), cardiac index (CI), systemic vascular resistance (SVR), and respiration rate (RR).~Translated with www.DeepL.com/Translator (free version)
Study: NCT02171104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cALD HR-D (High-Risk, Regimen D)
Description: N-acetylcysteine, celecoxib, vitamin E and alpha lipoic acid start day of admission (prior to conditioning regimen) and continue through day +100
Study: NCT03253848

Intervention type: OTHER
Intervention: Best Practice
Description: Discussion between doctors and APL expert

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Intervention: Supportive Care
Description: Receive simplified guidelines and support
Study: NCT04123132

Intervention type: OTHER
Intervention: Kinesiophobia
Description: The presence of kinesiofobia in patients with metabolic syndrome
Study: NCT01576133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPABLE
Description: Occupational therapy visits plus nursing visits plus handyman repair

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention visits
Description: Participants in the attention control arm will receive 10 one hour visits over the course of 16 weeks. These visits will consist of sedentary activities
Study: NCT02319122

Intervention type: OTHER
Group type: OTHER
Intervention: High Intensity Interval Training
Description: See arm description

Intervention type: OTHER
Group type: OTHER
Intervention: Progressive Resistance Training
Description: See arm description
Study: NCT00042198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: Up to 12 weekly, individual, hour-long sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Stress Management
Description: Up to 12 weekly, individual, hour-long sessions, focusing on application of relaxation and other stress management techniques to depressogenic stressors
Study: NCT04928053

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ocytocine dosage and genetic analyse
Description: All patients are assessed using 4 paradigms: Reading the Mind in the Eyes Test (RMET), Interpersonal Reactivity Index (IRI), Empathy Quotient (QE), and a modified Delay Discounting task. They have a blood prelevment
Study: NCT02001623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisotumab Vedotin (HuMax-TF-ADC)
Study: NCT01070888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/Formoterol
Description: Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol
Description: Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Budesonide 180mcg, 2 puffs twice daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide 180mcg, 2 puffs twice daily for 2 weeks
Study: NCT04152616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrumental evaluation of posture
Description: After a time of installation of the Optitrack® device's and two accelerometers (one placed on the subject's trunk facing the sternum fixed with a headband and the second at the level of the head also held with a headband), the subject will perform an evaluation of the balance sitting on the sensor pad; the movements of the head and trunk will be analyzed by the Optitrack® device and by the two accelerometers.~The subject will perform 4 30-second tests, two with eyes open and two with eyes closed. A rest period may be taken between each assessment depending on the subject.~During these evaluations, a physiotherapist will be present to avoid the risk of falling.~After a rest period of 30 minutes, a new assessment of the sitting posture will be carried out to assess the reproducibility of the tools (sensor pad, accelerometers, Optitrack®).
Study: NCT04455516

Intervention type: PROCEDURE
Intervention: Meniscus repair; partial meniscectomy
Description: 69 cases of meniscus repair (repair group) and 96 cases of partial meniscectomy (partial meniscectomy group), were retrospectively analyzed. The 69 patients of the repair group were divided into the nonfailure group (62 cases) and the failure group (7 cases) depending on the repair effect.

Intervention type: PROCEDURE
Intervention: Meniscus repair; partial meniscectomy
Description: 69 cases of meniscus repair (repair group) and 96 cases of partial meniscectomy (partial meniscectomy group), were retrospectively analyzed. The 69 patients of the repair group were divided into the nonfailure group (62 cases) and the failure group (7 cases) depending on the repair effect.

Intervention type: PROCEDURE
Intervention: Meniscus repair; partial meniscectomy
Description: 69 cases of meniscus repair (repair group) and 96 cases of partial meniscectomy (partial meniscectomy group), were retrospectively analyzed. The 69 patients of the repair group were divided into the nonfailure group (62 cases) and the failure group (7 cases) depending on the repair effect.
Study: NCT02452242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: 25, 50, 75, 100, 150 mg, i.e. 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
Study: NCT02091336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: patients treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: patients treatment
Study: NCT00364286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib (BMS-354825)
Description: 50mg Orally twice daily
Study: NCT01061424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community health worker
Description: community health worker provides home visits for education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mailed information
Description: information on asthma is mailed to the home on the same schedule as the other arm
Study: NCT06030713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Cord clamping before or after antibiotic (cefazolin) prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Cord clamping before or after antibiotic (cefazolin) prophylaxis
Study: NCT02491554

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional AC-PC based implantation of ACTIVA INS DBS system
Description: Conventional AC-PC based implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the thalamic/subthalamic region (Vim-cZI).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-tractography guided implantation of ACTIVA INS DBS system
Description: MR-tractography guided implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the DRT.
Study: NCT00470899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drainage of placenta of fetal blood
Study: NCT03556137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FTC-146
Description: Adult participants will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FTC-146
Description: Adult participants will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.
Study: NCT04779892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: 100mg/vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: 100mg/vial
Study: NCT01886430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Description: Functional electrical stimulation for 10 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo electrical stimulation
Description: Placebo electrical stimulation for 10 days
Study: NCT02263508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Talimogene laherparepvec administered by intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Talimogene laherparepvec administered by intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered at a dose of 200 mg as an intravenous infusion over approximately 30 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Administered at a dose of 200 mg as an intravenous infusion over approximately 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered at a dose of 200 mg as an intravenous infusion over approximately 30 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intratumoral injection
Study: NCT02574026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychomotor tasks
Description: the acquisition of data will be performed in one unique session no drug administration no surgery
Study: NCT03521037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib camsylate
Description: In Part I, eligible patients will receive a single oral dose of 600 mg rucaparib followed by intensive plasma PK sampling up to Day 7 (hour 144). In Part II, patients may continue to receive continuous oral rucaparib in 28 day cycles.
Study: NCT01750463

Intervention type: OTHER
Intervention: Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor
Description: Patients admitted to PICU requiring hemoglobin monitoring will have a total hemoglobin (SpHb) assessment from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.

Intervention type: OTHER
Intervention: Standard Laboratory Blood Draw and Hemoglobin Analysis
Description: Patients admitted to PICU requiring hemoglobin monitoring will have a reading from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
Study: NCT01773980

Intervention type: OTHER
Intervention: Clinic Intervention
Description: The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.

Intervention type: OTHER
Intervention: Clinic Intervention
Description: The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.

Intervention type: OTHER
Intervention: Patient Intervention
Description: The patient intervention consists of a single 90-minute interactive in-person session.

Intervention type: OTHER
Intervention: Patient Intervention
Description: The patient intervention consists of a single 90-minute interactive in-person session.
Study: NCT02631148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 2mg controlled release melatonin tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet identical to circadin
Study: NCT01566708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuro-Music Therapy immediately
Description: 20 patients are randomized to receive Neuro-Music Therapy immediately. Neuro-Music Therapy takes 5 days and comprises 9 consecutive 50-minutes sessions of individual therapy. Immediately before and after treatment extensive diagnostics are performed, including psychological assessment, functional neuroimaging and electro-physiological examinations.
Study: NCT04014582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communal Coping Intervention
Description: This intervention aims to foster a shared appraisal and collaboration through: the discussion of past joint coping, education about communal coping (e.g. what it is and why it is beneficial), and discussions to foster the perception of diabetes as shared. Participants in the intervention group will also create collaborative action plans to increase collaboration. Couples in the intervention group will also receive two daily text messages-one a general reminder to engage in communal coping and the other one of the collaborative intentions they created during the in-person session. These couples will also receive a brief diabetes education.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education
Description: Couples in the diabetes education group will receive a brief diabetes education and complete individual implementation intentions. Patients will create implementation intentions related to diabetes and partners will create implementation intentions that are not related to health.
Study: NCT01682629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Debriefing Script
Description: A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. It was developed in iterative steps: (a) review of PALS learning objectives; (b) categorization of script content; (c) development of scripted language; (d) formatting into a cognitive aid and (e) pilot testing script for usability with subsequent edits before implementation in the study.~All novice instructors received the scenario 2 weeks prior to the study session. Instructors randomized to scripted debriefing were also given the script with no instruction on how to use it except on the day of the study, to use and follow the script as closely as possible during the debriefing session. All instructors held a clipboard while observing the simulation session; to hold the debriefing script and/or take notes. This allowed for blinding of the video reviewers as to which study arm the team had been randomized. Debriefing sessions were limited to 20-minutes in duration.
Study: NCT01566708

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuro-Music Therapy after waiting time
Description: 20 Patients were randomized to receive Neuro-Music Therapy after a waiting period not exceeding 6 weeks. Within this waiting time, patients undergo exactly the same diagnostic procedure as the patients of the treatment group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music-therapeutical stress management coaching
Description: 20 non-tinnitus controls matched in age, gender and hearing ability receive a music-therapeutical stress coaching program. This intervention is based on the main treatment components of the Neuro-Music Therapy for acute tinnitus with alterations of the tinnitus specific elements. Immediately before and after this five-day coaching, controls undergo exactly the same diagnostic procedure as the patients of the treatment group.
Study: NCT04292054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: active intervention
Description: The antibiotic prophylaxis will be cefazolin 2 g, or piperacilline-tazobactam 4 g, powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo intervention
Description: The control group will received, as placebo NaCl 0.9% solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
Study: NCT03737682

Intervention type: DIAGNOSTIC_TEST
Intervention: ENzyme linked immunity-sorbet assays
Description: Hemostasis achievement reflecting inflammatory status of the pulp based on cytokine levels

Intervention type: DIAGNOSTIC_TEST
Intervention: ENzyme linked immunity-sorbet assays
Description: Hemostasis achievement reflecting inflammatory status of the pulp based on cytokine levels
Study: NCT00873691

Intervention type: DEVICE
Intervention: ICD
Description: Intervention isn an ICD. Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.

Intervention type: DEVICE
Intervention: ICD
Description: Intervention isn an ICD. Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
Study: NCT02894242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P Deimos Nasal Pillows Mask
Description: Investigative Nasal Pillows Mask to be used for OSA therapy
Study: NCT02130128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LungPoint ATV System
Description: The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
Study: NCT06246435

Intervention type: OTHER
Intervention: moderate aerobic exercise

Intervention type: OTHER
Intervention: moderate aerobic exercise
Study: NCT00842049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumbar Drain (Medtronic lumbar drainage system)
Description: Insertion of lumbar drain to drain cerebrospinal fluid

Intervention type: OTHER
Group type: OTHER
Intervention: No lumbar drain
Description: No lumbar drain
Study: NCT01465724

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system.
Study: NCT03336424

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-invasive investigations
Description: Ultrasound, blood tests, urine analysis and culture, uroflowmetry

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-invasive investigations
Description: Ultrasound, blood tests, urine analysis and culture, uroflowmetry

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Invasive investigations
Description: Cystomanometry, pressure flow study, EMG
Study: NCT01796782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeloda
Description: Xeloda dose is calculated according to body surface area.The recommended dose is 1000 mg/m² administered orally twice daily (morning and evening; equivalent to 2000 mg/m² total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QYHJ Granules
Description: 1-4 bags bid , days 1-42, every 6 weeks